Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- 18 years - 85 years
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 100 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding. Crohn's disease and ulcerative colitis are the 2 main types of IBD. Researchers want to conduct a natural history study to learn more about whether genetic factors can cause IBD; how immune cells contribute to IBD; and how diet, drugs, and disease affect those cells.
Objective:
To better understand IBD over time.
Eligibility:
Adults aged 18 to 85 years with Crohn's disease, ulcerative colitis, or another IBD. Their healthy relatives are also needed.
Design:
Affected participants will have clinic visits every 6 months for 3 years.
Once a year, they will have these procedures:
A physical exam with blood and stool samples.
Ultrasound of the abdomen. A wand will be rolled over the skin. It uses sound waves to capture images of the intestines.
Magnetic resonance imaging (MRI) scan. They will lie on a table that slides into a tube. Magnetic fields will capture images of the intestines.
Colonoscopy. A long, flexible tube with a video camera will be inserted into the rectum to view the entire colon. Up to 12 tissue samples may be taken.
Upper endoscopy, for those with Crohn's disease. A long, thin tube with a camera will be inserted through the mouth and into the first part of the small intestine. Up to 12 small tissue samples may be taken.
Questionnaires. Participants will answer questions about their disease and their diet.
Midyear visits will include a physical exam, blood and stool collection, ultrasound, and questionnaires
Healthy relatives will have 1 blood draw for genetic tests.
Read the full description
Study Description:
This is a single-site, hypothesis-generating natural history study aiming to follow participants with inflammatory bowel disease. Participants will be followed long-term with a focus on immunophenotyping their conditions. Adult family members of participants will also be invited to enroll to provide blood samples for immune and genetic analyses.
Objectives:
Primary Objective: To collect longitudinal clinical data and specimens, with the goal of identifying novel biomarkers correlating with disease activity or response to therapy
Secondary Objectives:
1. To identify the dynamic molecular and immunological changes associated with chronic GI inflammation and mechanisms of response to FDA approved (biologic and small molecule inhibitors) therapies for IBD
2. To study the molecular genetics underlying chronic GI inflammation
3. To longitudinally quantify and characterize the nutritional status, food components, and overall diet of patients with IBD
Endpoints:
Primary Endpoint:
1\. Longitudinal collection of clinical data, biospecimens, and disease assessments at 6-month intervals over at least 3 years
Secondary Endpoints:
1.A) Mean change over baseline of immune cell populations, cellular transcript and protein expression, and cytokine levels in peripheral blood and mucosal tissue across at least 3 study visits during a two-year period.
1.B) Assessment of disease activity (endoscopic evaluation, and histopathology) at each endoscopy and evaluation of progression of disease activity across at least 3 endoscopies during a two-year period. If a treatment is implemented, then disease activity will be assessed and compared over consecutive endoscopies.
1. C) Identification of molecular patterns or immune signatures that correlate with disease activity and response to treatment
2. A) Quantification of gene expression data and its trajectory over the course of disease and after therapy
2.B) Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype
3.A) To establish positive or negative correlations between specific food components and nutrient amounts with disease activity obtained from questionnaires over 12 months
3.B) to establish correlations with nutritional data and the microbiome over 12 months
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
- INCLUSION CRITERIA
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Affected Participant cohort:
1. Adults 18 - 85 years of age
2. History of:
1. a verifiable diagnosis of Crohn's disease, ulcerative colitis, or IBD known to be associated with a co-existing condition (such as CTLA4 deficiency or common variable immune deficiency) and which is supported by characteristic clinical features, radiographic or endoscopic findings, or consistent histopathologic mucosal changes related to chronic inflammation; and/or
2. a defined genetic syndrome/mutation linked to inflammatory bowel disease risk with or without symptoms or findings consistent with IBD
3. Presence of a referring community physician who would be able to manage care outside of NIH
Unaffected family member of participant: immediate relative to the enrolled participant (mother, father, sibling, or adult child) may be recruited and enrolled to improve interpretation of genetic results or expand the phenotype of the IBD
1. Adults 18 - 99 years of age
2. In good general health
3. No medical diagnosis of IBD
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Unable or unwilling to provide informed consent
2. Evidence of significant medical illnesses that the investigators feel may interfere with study evaluations and procedures
Study population
Patients with known or suspected inflammatory bowl disease
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Affected participants
participants affected with inflammatory bowel disease
Unaffected family members
unaffected family member of participant
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
To collect longitudinal clinical data and specimens, with the goal of identifying novel biomarkers correlating with disease activity or response to therapy
Time frame: 3 years
Not reported in this registry record.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
National Institutes of Health Clinical CenterBethesda, Maryland, United StatesRecruiting
Study team and timeline
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- Nov 5, 2026 Actual
- Primary completion
- Jun 1, 2036 Estimated
- Study completion
- Jun 1, 2036 Estimated
- First posted
- Jun 2, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026
